For example, by targeting PTEN, miR-22 activates PI3K/AKT signaling pathway, resulting in downregulation of p27(-Kip1) and overexpression of Survivin and Ki-67 proteins in chronic lymphocytic leukemia B cells and acts as oncogene [55]. This evidence concerns the gene AKT1 and B-cell chronic lymphocytic leukemia.